Bio-Rad Laboratories (BIO) Non-Current Deffered Revenue (2015 - 2016)
Bio-Rad Laboratories' (BIO) quarterly Non-Current Deffered Revenue came in at $4.4 million in Q3 2016, up 17.55% quarter-over-quarter from $3.7 million in Q4 2015.
Powered by 
Analysis
Bio-Rad Laboratories (BIO) Non-Current Deffered Revenue (2015 - 2016) Analysis & Trends
Bio-Rad Laboratories (BIO) has reported Non-Current Deffered Revenue for 2 consecutive years, with $4.4 million the latest figure, recorded in Q3 2016.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $4.4 million in Q3 2016; TTM through Sep 2016 was $4.4 million, a N/A change from a year earlier, with the FY2015 full-year figure at $3.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $4.4 million for Q3 2016 at Bio-Rad Laboratories, up from $3.7 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $4.4 million in Q3 2016 and troughed at $3.7 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 225.48 Bn | 221.41 Bn | 8.34 Bn | - |
| 2 | Danaher | 144.42 Bn | 140.08 Bn | 3.61 Bn | - |
| 3 | Agilent Technologies | 40.86 Bn | 39.11 Bn | 1.04 Bn | - |
| 4 | Illumina | 30.97 Bn | 29.80 Bn | 770.00 Mn | - |
| 5 | Revvity | 13.85 Bn | 12.83 Bn | 416.87 Mn | - |
| 6 | Bio-Techne | 11.27 Bn | 11.01 Bn | 211.39 Mn | - |
| 7 | Bio-Rad Laboratories | 10.11 Bn | 8.49 Bn | 345.80 Mn | - |
| 8 | Repligen | 9.33 Bn | 8.31 Bn | 110.04 Mn | - |
| 9 | 10x Genomics | 8.77 Bn | 8.21 Bn | 112.50 Mn | 9.68 Mn |
| 10 | Bruker | 8.30 Bn | 8.09 Bn | 416.00 Mn | - |